Merck’s Oral PCSK9 Inhibitor and Nurix’s BTK Degrader Among ACS First Disclosures
The First Disclosures section of the 2023 ACS Spring Meeting in Indianapolis, organized by GSK’s Nikki Goodwin, covers three novel small molecules and an ADC this year. The molecules include: More notes on each of the molecules and why they matter appear below. This page will continue to be updated after the conference. MK-0616, Merck’s…
Molecules of the Month – February 2023
A Merck HIV inhibitor with targeted cell-killing activity as a possible approach to finally eradicate HIV, a KIT-selective inhibitor with best-in-class potential for the treatment of GIST, a first-in-class dual ETA/AT1 antagonist recently approved for the rare kidney disease IgA nephropathy are just some of the examples for this month’s MOTM. Learn more about the…
Terlipressin: Longer Peptide Effect Half-Life via an Active Metabolite
On Monday, Mar. 27th (12:15 PM ET), our Drug Hunter team will be sponsoring a luncheon at ACS Spring 2023 in Indianapolis with a presentation on scientific gems from 2022’s drug approvals (request an invitation here). Each newly approved drug has an interesting scientific story, and you can see our overview of all 36 of…
Molecules of the Year 2022
In 2022, Drug Hunter highlighted 120 Molecules of the Month with structures or stories that were published for the first time, or had approvals or significant disclosures of new data. They were selected from tens of thousands of research articles published by leading institutions around the world. Here is the final list of the top…
Drug Hunter Journal Club: February 2023
While the Molecules of the Month are being selected and our deep dive reviews are being prepared, you can find early highlights from our team’s journal club from February 2023. Check out AstraZeneca’s preclinical SERD, Merck’s Ph. I c-KIT inhibitor, University of Michigan’s STAT5 PROTAC degrader, and more snippets to jumpstart your reading! Want updates…
Another KRASG12C Inhibitor in Ph. III, Bayer’s Massive FXIa Ph. III Clinical Trial, and 21 Other Molecules in the News
In this update of small molecules in the news for February 2023, we will cover recent: – Molecules in Motion: clinical trial updates and FDA filings – Negative Readouts: halted, discontinued or altered clinical trials – Million-Dollar Molecules: recent M&A’s, IPOs, and other fundraising – Potential Approvals: recent NDA filings and upcoming PDUFA dates – Where…